Navigation Links
Medicare Will Pay for Prostate Cancer Drug
Date:7/1/2011

By Steven Reinberg
HealthDay Reporter

THURSDAY, June 30 (HealthDay News) -- The cost of Provenge, an expensive and newly approved therapeutic prostate cancer vaccine, will be covered by Medicare for men with metastatic prostate cancer, the agency announced late Thursday.

The vaccine, made by the Dendreon Corp., costs $93,000 per patient and extends survival by about four months on average, according to results from clinical trials. A panel of experts convened by Medicare gave the nod for coverage last November, but the agency has only now announced it would cover the treatment.

"We are optimistic that innovative strategies may improve the experience of care for our beneficiaries who have cancer," Dr. Donald M. Berwick, administrator of the Centers for Medicare & Medicaid Services (CMS), said in an agency news release. "CMS is dedicated to assuring that these patients can seek the treatments they need in accordance with their wishes."

Research does suggest that the vaccine can extend the lives of men with cancer that has spread beyond the prostate. One study, published in July 2010 in the New England Journal of Medicine, found that the vaccine extended the lives of men with metastatic tumors resistant to standard hormonal treatment, compared with no treatment. And the therapy involved less toxicity than chemotherapy.

Provenge is a therapeutic (not preventive) vaccine made from the patient's own white blood cells. Once removed from the patient, the cells are treated with the drug and placed back into the patient. These treated cells then trigger an immune response that in turn kills cancer cells, leaving normal cells unharmed. The vaccine is given intravenously in a three-dose schedule delivered in two-week intervals.

"The strategy of trying to harness the immune system to fight cancer has been something that people have tried to attain for many years; this is one such strategy," study lead researcher Dr. Philip Kantoff, a professor of medicine at Harvard Medical School and a medical oncologist at the Dana-Farber Cancer Institute in Boston, told HealthDay last November.

Another expert said the therapy, while far from a cure, "looks promising." Speaking at the time of the drug's approval by the CMS panel, Dr. Elizabeth Kavaler, a urologist at Lenox Hill Hospital in New York City, said that "in this unfortunate category of [hormone-resistant] patient, we have very little to offer. Adding months to a man's life is better than doing nothing, especially if the treatment involves minimal morbidity, as this vaccine promises."

The U.S. Food and Drug Administration approved Provenge in April 2010 for the treatment of prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment.

In his team's study, Kantoff's group randomly assigned 512 men to receive Provenge or a placebo. All of the patients had advanced prostate cancer that had proven resistant to standard hormonal therapy.

On average, men receiving Provenge lived 4.1 months longer than men receiving a placebo, the researchers found. Average survival was 25.8 months for men in the Provenge group, compared with 21.7 months for men in the placebo group, meaning that Provenge extended survival by 22 to 25 percent, Kantoff said.

He contends that if the vaccine were used by men with less severe disease, survival might be extended even longer.

"Theoretically, if you take people with less disease and you stimulate the immune system, you could have a more profound effect, but we don't really know that yet," he said.

Compared with other treatments, such as chemotherapy, radiation and hormone therapy, Provenge has been touted as having fewer and less severe side effects. In this trial, the most common side effects were chills, fever and headache, the researchers noted.

Commenting on the high cost of Provenge, Kantoff said that "this is a treatment given over a four-week period, as opposed to other treatments that are given over many months, where the costs can be high as well, if not comparable to or more expensive [than Provenge]."

More information

For more information on prostate cancer, visit the American Cancer Society.

SOURCES: June 30, 2011, news release, Centers for Medicare & Medicaid Services; Philip Kantoff, M.D., professor, medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, Boston; Elizabeth Kavaler, M.D., urologist, Lenox Hill Hospital, New York City; July 29, 2010, New England Journal of Medicine; Wall Street Journal


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Most Medicare Patients With Cancer Get Good Surgical Care: Study
2. Poll Finds Little Support for GOP Plan to Privatize Medicare
3. Medicare should employ new data sources, methods to ensure accuracy of geographic adjustments to payments
4. Medicare payment adjustments -- focus of new IOM report releasing June 1
5. Medicare improved Canadian doctors salaries: Queens University study
6. Fewer Medicare Patients Hospitalized for Heart Trouble
7. Study Questions Overuse of Colonoscopy in Medicare Patients
8. Colorectal cancer screening rates on rise among Medicare beneficiaries due to expansion of coverage
9. Medicares Drug Coverage Gap to Shrink Away Under Health Care Reform
10. Brigham and Womens Hospital selected to participate in Medicare imaging demonstration project
11. Health care reform can help align preventive care recommendations with Medicare coverage
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Medicare Will Pay for Prostate Cancer Drug 
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement ... Vice President of North American Capital Sales at HTG Molecular . ... in the commercialization of the HTG EdgeSeq system and associated reagents in North America. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, ... stem (iPS) cells and other difficult to transfect cells, announces its launch of ... PluriQ™ G9™ Gene Editing System is a complete system for culturing and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
Breaking Medicine Technology: